
Startup accelerator running programmes for early-stage and scaling technology founders in the North East of England

Life sciences investor financing biotech companies developing new therapies in Europe and the United States

Ysios Capital is a life sciences investor that finances biotechnology ventures working on new medicines. It looks for companies tackling conditions where patients have few treatment options.
The firm's portfolio is a mix of biotech companies based in Europe and the United States. Examples described on its site include a bleeding-prevention protein developer, a gene therapy company for rare diseases, an antibody-drug conjugate cancer developer, an HIV vaccine company and a nanotechnology cancer company.
Profile written by TrustList from the business's own published information, Oct 2026.
2 images — click to enlarge
As of 2026-10-08. Organic ranks only; sponsored placements are never ranks.
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Ysios Capital.
Similar listings buyers compare against this one.

Startup accelerator running programmes for early-stage and scaling technology founders in the North East of England

Product discovery software for B2B and B2C sellers, covering search, guided selling and product content

Member-based investor group funding early-stage companies through monthly review and a chapter roadshow

Startup accelerator and early-stage investor running intensive batches for new technology founders

Global venture capital firm and accelerator backing early-stage technology founders, formerly called 500 Startups

TriWest Capital Partners
Everything here links back to the same verified catalogue. Pick your next stop.